To further investigate these effects, we examined the effects of BPC157 on the expression of these growth factors and their receptors in HUVECs
otherwise 100,- Zone 1 (EU) including Switzerland and United Kingdom (GB): Belgium, Bulgaria, Denmark (except Faroe Islands, Greenland), Estonia, Finland (except land Islands), France (except overseas territories and departments), Greece (except Mount Athos), United Kingdom (GB, except Channel Islands), Ireland, Italy (except Livigno and Campione d'Italia), Croatia, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands (except non-European territories), Austria, Poland, Portugal, Romania, Sweden, Slovakia, Slovenia, Spain (except Canary Islands, Ceuta + Melilla), Czech Republic, Hungary, Cyprus/Republic (except northern part), including Switzerland Zone 2 (Europe excluding the EU): land Islands (Finland), Andorra, Albania, Armenia, Azerbaijan, Mount Athos (GR), Bosnia and Herzegovina, Campione d'Italia (IT), Ceuta (E), Faroe Islands (DK), Georgia, Gibraltar (GB), Greenland (DK), Guernsey (GB), Iceland, Jersey (GB), Canary Islands (E), Kazakhstan , Kosovo (Serbian province), Liechtenstein, Livigno (IT), Macedonia, Melilla (E), Moldova (Republic), Montenegro (Republic), Norway, Russian Federation, San Marino, Serbia (Republic), Turkey, Ukraine, Vatican City, Belarus, Cyprus/Republic (northern part) Zone 3 (World): Egypt, Algeria, Bahrain, Iran, Iraq, Israel, Yemen, Jordan, Canada, Qatar, Kuwait, Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syria Tunisia, USA, United Arab Emirates Zone 4 (Rest of the world): All countries and territories not assigned to Zones 1, 2 or 3
Analysis of splenocytes demonstrated decreased CD4+IL-4+ and CD4+IL-17-secreting T cells when treated with high dose luteolin, which corresponded with the re-stimulation of splenocytes resulting in significant decreases in IL-4 expression [162]
Duration of BPC-157 Use BPC-157 is typically used in cycles rather than indefinitely
